BRAF and melanoma: Brady et al. demonstrated that the use of TM, which was tested in vivo by Ishida et al., reduces the levels of Cu and activation of the MAPK pathway, resulting in the inhibition of BRAFV6ooE-positive melanoma tumor cell growth of cells resistant to BRAF and Mek inhibitors.